A resource of Calculate by QxMD at https://www.qxmd.com/calculate
Over 400 decision support tools available • get the app for iOS or Android at qx.md/calculate
Supplementary Table 4: Summary table of RCTs examining the effect of dopamine vs. placebo for the treatment of AKI.
Supplementary Table 5: Evidence profile of RCTs examining fenoldopam vs. control for the prevention of AKI.
Supplementary Table 6: Summary table of RCTs examining the effect of fenoldopam for the prevention of AKI.
Supplementary Table 7: Evidence profile of RCTs of fenoldopam vs. placebo for the treatment of AKI.
Supplementary Table 8: Summary table of RCTs of examining the effect of fenoldopam for the treatment of AKI.
Supplementary Table 9: Summary table of RCTs of nesiritide vs. control for the prevention of AKI.
Supplementary Table 10: Evidence profile of RCTs examining anaritide vs. control for the prevention of AKI.
Supplementary Table 11: Summary table of RCTs examining the effect of anaritide vs. control for the prevention of AKI.
Supplementary Table 12: Evidence profile of RCTs examining anaritide vs. placebo for the treatment of AKI.
Supplementary Table 13: Summary table of RCTs examining the effect of ANP vs. placebo for the treatment of AKI.
Supplementary material is linked to the online version of the paper at http://www.kdigo.org/clinical_practice_guidelines/AKI.php
Do you have an enquiry or suggestion? Get in touch with us through Twitter @QxMD, Facebook QxMD, or email contact@qxmd.com